Novacyt S.A. announced revenue guidance for the year 2019. For the year, the company announced that year end revenues from continuing operations will be approximately €13.1 million, a reduction of 5% (6% CER) on a consolidated basis compared to 2018. Excluding the Clinical Lab, which was sold in July 2019, revenue reduced by 2% (3% CER).